DISCLOSURE NOTICE: The information contained in this release is as of March 10, 2013. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.This release contains forward-looking information about a potential additional indication for Inspra, including its potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when supplemental drug applications may be filed with regulatory authorities for this potential additional indication for Inspra; decisions by regulatory authorities regarding whether and when to approve any supplemental drug applications that may be filed for this potential additional indication for Inspra as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
New Trial Results Support Treatment With Inspra (eplerenone) Within First 24 Hours Of Symptoms, In Addition To Standard Therapy, In Patients With Acute STEMI Without Heart Failure.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.